CardiovascularORALStandard
LYPQOZET
ATORVASTATIN CALCIUM; EZETIMIBE
Standard Dose
EQ 10MG BASE;10MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview LYPQOZET is listed in Drugs@FDA under application 206084 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient ATORVASTATIN CALCIUM; EZETIMIBE Form and strength TABLET;ORAL - EQ 10MG BASE;10MG Sponsor PHARMOBEDIENT Submission history Latest submission status date: 2021-02-16 00:00:00.
Structured Monograph
Clinical summary
Approval overview LYPQOZET is listed in Drugs@FDA under application 206084 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ATORVASTATIN CALCIUM; EZETIMIBE Form and strength TABLET;ORAL - EQ 10MG BASE;10MG Sponsor PHARMOBEDIENT Submission history Latest submission status date: 2021-02-16 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.